Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Infectious Disease Head Touts Diversity Of Post-Schering Merger Anti-Infective Portfolio

Executive Summary

BOSTON – Merck & Co.'s purchase of Schering-Plough created probably the most broad and comprehensive pipeline of anti-infective agents in the industry, according to Roger Pomerantz, Merck's senior vice president and global franchise head, infectious diseases.
Advertisement

Related Content

Novel Antibiotics At ICAAC Spur Optimism On Resistance Front
Novel Antibiotics At ICAAC Spur Optimism On Resistance Front
Merck's Backbone Is Cardiovascular, Infectious Disease After Pipeline Integration
True To Its Cancer Focus, Medarex Outlicenses C. Diff Therapy To Merck

Topics

Advertisement
UsernamePublicRestriction

Register

PS052631

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel